Kornimate/medical-research-clean huggingface dataset:
a comparison of totally intravenous and inhalation anesthesia for intraocular pressure during robot-assisted laparoscopic radical prostatectomy

Conditions: Prostate Cancer

Summary: robot-assisted laparoscopic radical prostatectomy (ralrp) has gained popularity during the past decade and has widely replaced conventional open prostatectomy in many institutions due to reduced blood loss, nerve sparing, less postoperative pain and shorter hospital stay. however, laparoscopic surgery is performed with intraperitoneal carbon dioxide insufflation, which leads to increased intraocular pressure (iop). in particular, robot-assisted laparoscopic radical prostatectomy (ralrp) usually requires a steep trendelenburg position and often prolonged insufflation times, which is known to effect the increase in iop during surgery and may result in ophthalmic complications such as postoperative vision loss (povl). the majority of patients undergoing ralrp is old aged and often present with comorbidities. advanced age, underlying diabetes mellitus (dm) or hypertension renders the patient vulnerable to damage due to increased iop. moreover, the possibility of the patient having undiagnosed glaucoma is also increased, and therefore methods to prevent such complications are needed. as of now, intravenous hypnotic agents, inhalation anesthetics and opioids have been reported to decrease iop by relaxing extraocular muscle tone and increasing aqueous humour outflow to some extent. among these agents, propofol has been reported to be more effective than other inhalational anesthetics in decreasing iop. the goal of this prospective, randomized controlled trial is to compare the effect of propofol and sevoflurane on iop in patients undergoing ralrp in the steep trendelenburg position with carbon dioxide pneumoperitoneum.


Eligibility criteria:
inclusion criteria: 1. asa class 1 or 2 2. adults over the age of 20 and under 70 3. patients undergoing robot-assisted laparoscopic radical prostatectomy 4. patients that have given informed consent exclusion criteria: 1. patients with known ophthalmic diseases (glaucoma, diabetic retinopathy, cataract, retinal detachment) 2. patients with history of ophthalmic surgery 3. patients with high baseline intraocular pressure (over 30 mmhg) 4. patients with active cardiac conditions (unstable angina, congestive heart failure) 5. patients with uncontrolled hypertension (diastolic blood pressure \> 110 mmhg) 6. patients with history of allergic reactions to propofol 7. illiterate patients

Keywords: intraocular pressure, total intravenous anesthesia, laparoscopic prostatectomy
lactated ringer's solution to prevent post-ercp pancreatitis

Conditions: Post-ERCP Acute Pancreatitis

Summary: this is a randomized, double-blinded, controlled trial. this study is a head to head comparison of normal saline (ns) infusion versus lactated ringer's (lr) infusion in patients, with the primary outcome of post-ercp pancreatitis occurrence. patients will be randomized to either the ns infusion group or the lr infusion group. ivf will be started pre-procedurally and will be continued throughout the procedure. a ivf bolus will be given at the end of the procedure and then continued as a continuous infusion. our null hypothesis is that there will be no significant difference in the rate of occurrence of post-ercp pancreatitis between the infusion of lr and ns solutions. our alternative hypothesis is that patients receiving lr solution infusion will experience a decreased rate of post-ercp pancreatitis compared to patients receiving ns solution infusion.


Eligibility criteria:
inclusion criteria: i. possession of one of the following criteria which places the patient at high risk for post-ercp pancreatitis and/or if patient is to undergo a planned endoscopic intervention deemed at high risk: 1. suspicion of oddi dysfunction 2. personal history of post-ercp pancreatitis 3. more than 8 cannulation attempts 4. precut sphincterotomy 5. endoscopic papillary balloon dilation of an intact sphincter 6. endoscopic pancreatic duct sphincterotomy 7. ampullectomy 8. total bilirubin \< 1.0 ii. or possession of two or more of the following minor criteria: 1. female sex 2. age under 50 years 3. personal history of recurrent acute pancreatitis 4. pancreatic duct injection leading to "acinarization" or over 3 pancreatic duct injections 5. pancreatic duct cytology acquisition exclusion criteria: 1. patients aged less than 18 2. inability to provide informed consent 3. pregnancy 4. active acute pancreatitis 5. any contraindication to aggressive ivf hydration: evidence of clinical volume overload (peripheral or pulmonary edema), respiratory compromise (oxygen saturation \ 150 meq/l 6. if patient does not undergo a planned high-risk intervention 7. if patient does not possess complete criteria which places them at high risk for post-ercp pancreatitis 8. patients with cholangitis 9. patients with chronic and/or active pancreatitis 10. patients with a true nsaid allergy 11. patients greater than or equal to 75 years old

Keywords: post-ercp acute pancreatitis normal saline lactated ringer's
pilot study to investigate the effects of increased dialysate magnesium and dialysate bicarbonate on the calcification propensity of serum

Conditions: End Stage Renal Failure on Dialysis; Vascular Calcification

Summary: the study aims to determine the effect size of magnesium and bicarbonate supplementation as a basis for future randomized controlled trials aiming at the t50-guided improvement of hard clinical endpoints in dialysis patients.


Eligibility criteria:
inclusion criteria: * male or female hemodialysis patients ≥ 18 years of age * negative pregnancy test of female patients in child-bearing age * the patients have to be able to understand the character and the individual impact of the clinical study and they have to give written informed consent to participate in the study * start of chronic hemodialysis treatment ≥ 3 months ago * hco3- in venous plasma ≤23 mmol/l before the start of the last dialysis of the week * magnesium in venous plasma ≤ 1.45 mmol/l before the start of the first dialysis of the week * t50 ≥ 200 minutes. exclusion criteria: * pregnant or lactating subjects. a blood pregnancy test will be performed at the screening visit in female patients of childbearing age. * history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction within 12 months of study enrolment
does improving insulation and heating improve health?

Conditions: Asthma

Summary: the housing, heating and health study has enrolled 409 households with ineffective heaters, who have a child with asthma between 6 and 12 years. in the winter of 2005, houses were insulated and baseline measures taken of indoor temperatures, nitrogen dioxide, with more intensive indoor air quality monitoring in a sub-sample of 33 homes. objective data are being collected on the household's health and energy usage. the households randomly assigned to the intervention group will have new heaters installed over the summer. results will be available after the follow-up data collection in 2006.

1. introduction new zealand houses are relatively poorly constructed and maintained for the temperate climate and most homes are heated to less than the who recommended minimum winter temperature of 18°c. excess winter mortality is comparable to the levels in portugal and scotland. the group's previous housing, insulation and health study has shown that insulating existing homes leads to a small but significant improvement in health and energy consumption, but raised the question as to whether installing more sustainable heating could increase these gains. 2. study design we have enrolled 409 households, who use either plug-in electric heaters or unflued gas heating, and where there is a child with asthma, aged between 6 and 12 years. in the winter of 2005, uninsulated houses were insulated and baseline measures taken of indoor temperatures in the living room and the child's bedroom, and levels of nitrogen dioxide. intensive monitoring of indoor air quality is being carried out in a sub-sample of 33 homes. all members of the child's family have filled out detailed questionnaires of their health and the heads-of -household have completed a questionnaire on the characteristics of the household's energy usage. objective measures are also being collected of the household's fuel bills, the child's attendance at school and the family's health care utilisation. households are randomised so that the intervention group will have their choice of new, more efficient and sustainable heaters (heat pumps, wood pellet burners, or flued gas heaters) that heat more of the house and which emit no internal emissions installed over the summer. in the winter of 2006, follow-up measures will be taken and then the control households will receive their choice of new heaters.

Eligibility criteria:
inclusion criteria: * household has asthmatic child between 6 and 12, is living in study area, and will not be moving in the two years after applying to join the study. exclusion criteria: * heating of good quality and comparable to heater that will be installed by the study

Keywords: childhood asthma heating insulation respiratory symptoms
robotic assisted evacuation of subacute and chronic supratentorial deep hypertensive intracerebral hemorrhage

Conditions: Hypertensive Intracerebral Hemorrhage

Summary: robotic assisted evacuation of subacute and chronic supratentorial deep hypertensive intracerebral hemorrhage for accelerating functional rehabilitation (rescue-chain): a multi-center randomized controlled trial

background: hypertensive intracerebral hemorrhage (hich) is a devastating neurological disorder with high mortality and disability rates. secondary injury following hich may worsen motor function rehabilitation in subacute and chronic hematoma. hematoma evacuation has the potential to reduce mass effect and mitigate the neurotoxic effects. a per-protocol analysis identified a significant functional improvement in patients with minimally invasive surgery with thrombolysis achieving end of treatment (eot) goal ≤ 15ml. however, no surgical management of stabilized subacute or chronic hich have been reported before. therefore, we design this study in which we hypothesize this robotic assisted approach to hematoma eot goal ≤ 15ml would accelerate functional rehabilitation in subacute and chronic hich patients.

Eligibility criteria:
the inclusion criteria are hich patients who: (1) are ≥ 18 and ≤ 75 years old of either gender; (2) have evidence of supratentorial, deep-seated on ct scan with a volume of between 15 ml and 30 ml; (3) are within 24 h of ictus (\ 8, nih stroke scale (nihss)\>5, modified rankin scale (mrs) 3-5, and fma scale\<85; (8) fully understand the nature of the study and have signed informed consent. the exclusion criteria are: (1) hich caused by aneurysms, cerebrovascular malformations, tumors or trauma; (2) any pre-existing physical or mental disorder that could interfere with the functional assessment; (3) severe abnormal coagulation function, hematologic diseases or multiple hemorrhagic lesions; (4) excessive hematoma extending into the ventricular system with ventricular dilation; (5) concomitant diseases such as liver, kidney and heart failure; (6) rebleeding\>5 ml or with surgical indications before allocation; (7) poor adherence or other unsuitable situations for the trial as determined by the investigators; (8) pregnant female.

Keywords: randomized controlled trial hypertensive intracerebral hemorrhage subacute chronic robotic assisted evacuation function rehabilitation
trial to evaluate the efficacy of fluvastatin on certain markers

Conditions: Dyslipidemia

Summary: to analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. in addition, tolerability and safety will also be evaluated in a spanish population.


Eligibility criteria:
inclusion criteria: * patients \> 18 years patients that give their inform consent exclusion criteria: * pregnant women diabetic patients treated with statins for the year prior to study inclusion patients with contraindications listed in fluvastatin prescribing information other protocol-defined in and exclusion criteria may apply

Keywords: dyslipidemia, chronic renal disease, fluvastatin
iop reduction after anecortave acetate injection in glaucoma patients

Conditions: Glaucoma; Intraocular Pressure

Summary: introduction: ocular administration of glucocorticoids is a common and effective treatment for several ocular diseases. however it is often complicated with the elevation of intraocular pressure (iop). anecortave acetate (aa) is an analog of cortisol acetate and lacks the typical anti-inflammatory and immunosuppressive properties of glucocorticoids. the effect of its anterior juxtascleral depot (ajd) injection has been evaluated in cases of glaucoma caused by intravitreal triamcinolone acetonide, presenting impressive results. the purpose of this study is to evaluate the efficacy and safety of the aa injection as a possible antiglaucoma treatment alternative. methods: a prospective clinical study will be carried out including 30 glaucoma patients (30 eyes). after inclusion each patient will receive a single ajd injection of 30 mg of aa in the selected eye. main outcome measure include: intraocular pressure at 1st day, 7th day, 1st, 2nd and 3rd months.


Eligibility criteria:
inclusion criteria: * advanced glaucoma cases with surgery or cyclophotocoagulation indication (iop over 25 mmhg) * patients should be under maximum tolerated medication * low best corrected visual acuity (worse than 20/100) exclusion criteria: * under 18 or over 80

Keywords: glaucoma anecortave acetate intraocular pressure advanced glaucoma cases with uncontrolled iop
radiomics multifactorial biomarker for pulmonary nodules

Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Lung Diseases; Neoplasms; Pathology

Summary: the investigators aim to investigate the utility of radiomics to differentiate malignant nodules from benign nodules and invasive adenocarcinoma from non-invasive adenocarcinoma.

with the development of computed tomography (ct) equipment and the increasing use of lung cancer screening programs with low-dose ct, a growing number of early-stage lung cancers were detected so that a large number of patients have undergone surgery. although a number of radiological studies have been used morphological signs so-called semantic features to make a differential diagnosis, it is still hard to apply by clinician because pulmonary nodules especially ground-glass nodules and small size nodules have atypical radiology signs and have strong subjectivity from different observers. recently, ct-based radiomics, extracting the quantitative high-throughput features from medical images and facilitating clinical decision-making system, showed a good performance to predict diagnosis and prognosis of diverse cancer. therefore, the proposed project aims to develop and validate radiomics models based on ct images to identify malignant nodules and then to discriminate the different types of lung adenocarcinoma in patients with pulmonary nodules.

Eligibility criteria:
inclusion criteria: * intraoperative frozen section diagnosis and final pathology diagnosis are available * preoperative standard non-enhanced ct is available * pathologically confirmed exclusion criteria: * with a previous history of radiation therapy, chemotherapy or biopsy * the time interval between the ct examination and surgery was more than two weeks

Keywords: lung cancer ct frozen sections radiomics lung adenocarcinoma
improving efficacity of sleeve gastrectomy with naltrexone/bupropion extended-release tablet

Conditions: Obesity; Drug; Obesity, Morbid

Summary: the goal of this clinical trial is to assess the impact of combination therapy with naltrexone-bupropion (nb) in the post-operative period of sleeve gastrectomy (sg). on a) weight loss, b) resolution of comorbidities and c) eating behaviors. researchers will compare sg-nb group with sg-placebo group to see if they experience significantly higher excess weight loss (ewl) at 12 and 24 months and if there is a significantly higher percentage of patients with an ewl above 50% in the sg-nb group versus in the sg-placebo group. participants will be randomized 1:1 to sg in combination with nb versus sg with placebo. patients will be started one month after surgery on a progressive dose of naltrexone/bupropion extended-release or placebo. duration of therapy will be 24 months.both groups will benefit from behavioral and nutritional support.


Eligibility criteria:
inclusion criteria: * mbi above 30 kg/m2 with obesity-related comorbidity or above 35 kg/m2 without associated comorbidities. exclusion criteria: * revisional or reoperative surgery * pregnancy or planned pregnancy in the next 24 months * simultaneous use of other weight loss medication * uncontrolled hypertension * chronic opioid use or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal. * use of other bupropion-containing products * concomitant administration of monoamine oxidase inhibitors. * end-stage liver or kidney disease * concomitant use of cyp2b6 inhibitors (ticlopidine or clopidogrel) * concomitant administration of the antipsychotic thioridazine * seizure disorder or a history of seizures * cardiac pacemaker * current or prior diagnosis of bulimia or anorexia nervosa
blood and stool sample collection in subjects with a diagnosis of colorectal cancer or colorectal lesion: act fast

Conditions: Colorectal Cancer

Summary: the primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (crc).

participants will be 40 years of age or older, with a diagnosis of crc, at any stage, confirmed with a tissue biopsy or a colorectal lesion at least 1 cm in size suspicious for adenoma (including sessile serrated adenoma) or crc on a pre-enrollment colonoscopy, sigmoidoscopy, or computed tomography (ct) colonography. approximately 1500 participants will be enrolled.

Eligibility criteria:
inclusion criteria: 1. participant is 40 years of age or older. 2. participant has a diagnosis of crc, at any stage, confirmed with a tissue biopsy or a colorectal lesion at least 1 cm in size suspicious for adenoma (including sessile serrated adenoma) or crc on a pre-enrollment colonoscopy, sigmoidoscopy, or ct colonography. 3. postcolonoscopy, the residual lesion in the colon must be at least 1 cm in size as to require additional surgical excision or complex colonoscopic polypectomy. 4. participant understands the study procedures and is able to provide informed consent to take part in the study and authorization for release of relevant protected health information to the study investigator. exclusion criteria: 1. any previous cancer diagnosis (with the exceptions of basal cell or squamous cell skin cancers) and/or cancer related treatment (e.g., chemotherapy, immunotherapy, radiation, and/or surgery) within the past 5 years. 2. less than 7 days between colonoscopy and blood and/or stool specimen collection. 3. iv contrast (e.g., ct or mri) within 1 day \[or 24 hours\] before blood and/or stool collection. 4. participant has any condition that in the opinion of the investigator should preclude taking part in the study.

Keywords: blood draw sample collection stool dna
efficacy of over the counter (otc) povidone-ioldine 5% for treatment of acute or chronic blepharitis

Conditions: Blepharitis

Summary: objective: to determine the preliminary outcome of external over the counter (otc) povidone iodine (pi) application in the management of chronic and acute blepharitis vs. currently clinically accepted medical regimen, i.e. eyelid hygiene, antibiotic drops, or antibiotic/steroid ointments. methodology: one hundred adult patients with chronic and acute blepharitis will be enrolled and randomized into four groups. in group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% pi twice daily for 10 days and the other eye with no intervention. in group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% pi and the other eye will receive warm soaked eyelid wash. in group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% pi and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days. in group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% pi and the other eye will receive tobradex ointment applied to the lid margin. subjective variables assessed included itchiness, foreign body sensation and eyelid edema (grade 0-4). objective variables assessed included lid margin redness, meibomian gland plugging and presence/absence of collarets (grade 0-4). cultures of lid margin at the initiation and at the cessation of treatment were obtained.

final statiscial analysis for subjective and objective numerical values following treatment for each group of subjects (group 2,3,4) should show equal or almost equal efficacy in treatment of blepharitis.

Eligibility criteria:
inclusion criteria: * all potential subjects with symptomatic blepharitis examined to have blepharitis with healthy mental status, able to give consent, with/without co-existing medical consitions will be considered. exclusion criteria: * all subjects with history and/or probable history of allergic reaction to povidine-iodine, azithromycin, \& tobramycin/dexamethasone and all subjects who have mental disability and are unable to give direct consent will be excluded
study on breast cancer patient perspectives of exercise

Conditions: Breast Cancer

Summary: the goal of the study is to establish the feasibility/willingness of breast cancer patients to delay surgery to do an exercise program, or be randomized to an exercise training program following treatment, and to see if that willingness correlates with prior physical activity history.


Eligibility criteria:
inclusion criteria: * women, * breast cancer diagnosis, * all races will be included. exclusion criteria: * men, * those with no breast cancer (ductal carcinoma in situ), * pregnant women, * children
the alterations of metabolic adipo-myokines and body composition in end stage lung cancer

Conditions: Lung Cancer Metastatic

Summary: the investigators conduct this prospective study and wish to elucidate the association of serial change of body composition, serum adipo-myokines and adverse effect of chemotherapy and lung cancer prognosis

recently, the skeletal muscle was viewed as having biochemical function in additional to traditional biomechanical function. what's more important is that muscles could synthesize and release adipo-myokines during contraction. the adipo-myokines can affect muscle regeneration, muscle atrophy, muscle mass, autophagy, fatty acid oxidation and mitochondrial biosynthesis.studies have also found that exercise can promote the function of macrophages and regulate both pro-inflammatory and anti-inflammatory phenotypes, helping the body to establish a stable immune balance. since body composition can illustrate malnutrition status and cancer cachexia present, and body composition can be affected by serum adipo-myokines level. therefore, the investigators conduct this study and wish to see the association of serial body composition and serum adipo-myokines changes with lung cancer clinical outcomes and adverse effect of any anti-cancer regimen.

Eligibility criteria:
inclusion criteria: 1. diagnosis of lung cancer stage iii to stage iv 2. adults over 20 years old 3. daily performance status of 0- 2 exclusion criteria: 1. cardiac stents or pacemakers

Keywords: adipo-myokines body composition end stage lung cancer clinical outcomes